Evidence map›Paper›PMID 38729561›Full record

ReviewJournal of advanced research2025

Mesenchymal stem cell secretome for regenerative medicine: Where do we stand?

Catarina M Trigo, Joana S Rodrigues, Sérgio P Camões, Susana Solá, Joana P Miranda

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of advanced research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07544537 (A Prospective Comparative Study of Autologous Bone Marrow-Derived and Adipose Tissue-Derived Mesenchymal Stem Cells Versus Platelet-Rich Plasma and Standard Therapy in Patients With Organic Erectile Dysfunction), which is not on this map. Cited by 120 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07544537 phase2active not recruitingnot on this map

A Prospective Comparative Study of Autologous Bone Marrow-Derived and Adipose Tissue-Derived Mesenchymal Stem Cells Versus Platelet-Rich Plasma and Standard Therapy in Patients With Organic Erectile Dysfunction

TypeinterventionalSponsorNational Scientific Medical Center, KazakhstanRan2024 to 2026Enrolled100ConditionsErectile DysfunctionArmsAutologous Bone marrow-derived Mesenchymal Stem Cells (BMSC), Autologous Platelet-Rich Plasma (4 mL), Autologous Platelet-Rich Plasma (6 mL), Adipose Tissue Mesenchymal Stromal Cells (ADSC), Low-intensity radial shock wave therapy (Li-SWT)
3 · Its place in the literature

Who cites it

120 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Engineered NestinJournal of extracellular vesicles · 2026
    Article
  20. Article

60 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Catarina M TrigoResearch Institute for Medicines, Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal.
Joana S RodriguesResearch Institute for Medicines, Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal.
Sérgio P CamõesResearch Institute for Medicines, Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal.
Susana SoláResearch Institute for Medicines, Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal.
Joana P MirandaResearch Institute for Medicines, Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal. Electronic address: jmiranda@ff.ulisboa.pt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMesenchymal stem cell (MSC)-based therapies have yielded beneficial effects in a broad range of preclinical models and clinical trials for human diseases. In the context of MSC transplantation, it is widely recognized that the main mechanism for the regenerative potential of MSCs is not their differentiation, with in vivo data revealing transient and low engraftment rates. Instead, MSCs therapeutic effects are mainly attributed to its secretome, i.e., paracrine factors secreted by these cells, further offering a more attractive and innovative approach due to the effectiveness and safety of a cell-free product. AIM OF REVIEW: In this review, we will discuss the potential benefits of MSC-derived secretome in regenerative medicine with particular focus on respiratory, hepatic, and neurological diseases. Both free and vesicular factors of MSC secretome will be detailed. We will also address novel potential strategies capable of improving their healing potential, namely by delivering important regenerative molecules according to specific diseases and tissue needs, as well as non-clinical and clinical studies that allow us to dissect their mechanisms of action. KEY SCIENTIFIC CONCEPTS OF REVIEW: MSC-derived secretome includes both soluble and non-soluble factors, organized in extracellular vesicles (EVs). Importantly, besides depending on the cell origin, the characteristics and therapeutic potential of MSC secretome is deeply influenced by external stimuli, highlighting the possibility of optimizing their characteristics through preconditioning approaches. Nevertheless, the clarity around their mechanisms of action remains ambiguous, whereas the need for standardized procedures for the successful translation of those products to the clinics urges.

Indexed as

Mesenchymal Stem CellsMesenchymal Stem Cell TransplantationRegenerative MedicineSecretomeAnimalsCell DifferentiationExtracellular VesiclesHumansExtracellular vesiclesMesenchymal stem cellsPreconditioning strategiesRegenerative medicineSecretome

Identifiers

PMID38729561
PMCPMC11976416

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.